An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

• Status: Completed
• Trial end date: 2013-02-01

Summary

The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in patients who are infected with genotype 1 hepatitis C virus who relapsed after previous interferon-based therapy. Patients will also receive peginterferon alfa-2a and ribavirin as part of their treatment.

• Phase: Phase 3

Details

• Lead Sponsor: Janssen R&D Ireland
• Treatments: Interferon-alpha; Peginterferon alfa-2a; Ribavirin; Simeprevir